Seema Kumari

Has grant

Faculty

Medical College of Wisconsin
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Study on antimetastatic activity of coralyne, a protoberberines alkaloid and its synergistic effect with paclitaxel on breast cancer

Open Date:

Close Date:

Articles (24)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Objective: The present research aims to identify the bioactive compounds as therapeutic agents targeting cellular pathways in respiratory tract infection. Methods: Insilico docking was performed using Autodock Vina and visualized by Discovery Studio. MD (Molecular Dynamic) simulation was performed to identify the structural dynamics of the protein in a complex with a ligand. Results: The findings of the present study shows that curcumin (diferuloylmethane) exhibited the high binding affinity among ten natural ligands targeting TMPRSS2 (–7.2 kcal/mol), RdRp (–7.7 kcal/mol), 3CLpro (–7.6 kcal/mol), PLpro (–7.3 kcal/mol), and EndoU (–7.0 kcal/mol) and MD simulations showed structural stability with root mean square deviation (RMSD) values: TMPRSS2–curcumin (0.088–3.05 Å) confirmed by hydrogen bond analysis. Conclusion: The study provides a rationale that curcumin can be used as a therapeutic agent against respiratory tract infection, which regulates the expression of both pro-and anti-inflammatory factors.

Year:

2025

Mesothelin (MSLN), a glycoprotein-based tumor antigen, is elevated in several malignancies and it is related to a poor prognosis, as it enhances tumor aggression, dissemination and chemotherapy resistance. MSLN plays a crucial role in epigenetic and signal pathway regulation and it can be an important biomarker. MSLN targeting is in particular, associated with CA125/MUC16, which offers the potential to improve lung, pancreatic, colon and ovarian cancer detection as well as therapeutic strategies. MSLNtargeted therapies have shown favorable results, such as CAR NK cells, 227Th conjugate and CAR-T cells, which target mesothelin. Significant advancements can be achieved with novel techniques, such as mesothelin-targeting BiTEs and simultaneous CAR-T cells. Immunotherapies targeting mesothelin have the potential to completely transform the way cancer is therapy in patients with limited options. To fully comprehend the mechanisms of MSLN, more investigation is required to explore its role in cancer for improved patient outcomes. The complex control, cellular functions and clinical significance of MSLN in the advancement of cancer are highlighted in this review.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Bassel El-Rayes

Deputy Director

University of California, San Diego

UNITED STATES
View details

Ganji Purnachandra Nagaraju

The University of Alabama

UNITED STATES
View details